Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Timber Pharmaceuticals (TMBR)

Timber Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:TMBR
DateTimeSourceHeadlineSymbolCompany
28/11/202322:21GlobeNewswire Inc.Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE AmericanAMEX:TMBRTimber Pharmaceuticals Inc
18/09/202321:05GlobeNewswire Inc.Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceAMEX:TMBRTimber Pharmaceuticals Inc
21/08/202313:00GlobeNewswire Inc.Timber Pharmaceuticals to be Acquired by LEO PharmaAMEX:TMBRTimber Pharmaceuticals Inc
03/07/202321:05GlobeNewswire Inc.Timber Pharmaceuticals Discloses Communication From NYSE AmericanAMEX:TMBRTimber Pharmaceuticals Inc
20/06/202313:00GlobeNewswire Inc.Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
05/06/202313:00GlobeNewswire Inc.Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001AMEX:TMBRTimber Pharmaceuticals Inc
15/05/202321:15GlobeNewswire Inc.Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial ResultsAMEX:TMBRTimber Pharmaceuticals Inc
31/03/202321:28GlobeNewswire Inc.Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial ResultsAMEX:TMBRTimber Pharmaceuticals Inc
20/03/202312:00GlobeNewswire Inc.Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental DermatologyAMEX:TMBRTimber Pharmaceuticals Inc
24/02/202313:00GlobeNewswire Inc.Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
14/12/202213:30GlobeNewswire Inc.Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward OutlookAMEX:TMBRTimber Pharmaceuticals Inc
09/12/202221:05GlobeNewswire Inc.Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsAMEX:TMBRTimber Pharmaceuticals Inc
14/11/202213:00GlobeNewswire Inc.Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial ResultsAMEX:TMBRTimber Pharmaceuticals Inc
09/11/202213:20Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
08/11/202221:38Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
08/11/202217:09GlobeNewswire Inc.Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock SplitAMEX:TMBRTimber Pharmaceuticals Inc
03/11/202212:42Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
03/11/202212:22GlobeNewswire Inc.Timber Pharmaceuticals Announces Halt of Common Stock Trading  AMEX:TMBRTimber Pharmaceuticals Inc
26/10/202213:40TipRanksAnalysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)AMEX:TMBRTimber Pharmaceuticals Inc
25/10/202213:31Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
25/10/202213:00GlobeNewswire Inc.Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
03/10/202221:16Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
03/10/202215:56Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)AMEX:TMBRTimber Pharmaceuticals Inc
03/10/202214:00GlobeNewswire Inc.Timber Pharmaceuticals Announces $1.3 Million Registered Direct OfferingAMEX:TMBRTimber Pharmaceuticals Inc
14/09/202213:00GlobeNewswire Inc.Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital IchthyosisAMEX:TMBRTimber Pharmaceuticals Inc
12/09/202221:43Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
02/09/202221:17Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
29/08/202221:17Edgar (US Regulatory)Current Report Filing (8-k)AMEX:TMBRTimber Pharmaceuticals Inc
29/08/202221:05GlobeNewswire Inc.Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing DeficiencyAMEX:TMBRTimber Pharmaceuticals Inc
29/08/202213:00GlobeNewswire Inc.Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV CongressAMEX:TMBRTimber Pharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:TMBR